The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis
10.3760/cma.j.cn113694-20190912-00565
- VernacularTitle:抗降钙素基因相关肽及其受体单克隆抗体预防性治疗偏头痛有效性和安全性的系统评价
- Author:
Xiaoxiao LIU
1
;
Liqiong GUO
;
Miao WANG
;
Qinpeng WANG
;
Yanju ZHANG
;
Dandan SU
;
Guojuan WANG
;
Cheng LIANG
Author Information
1. 兰州大学第二临床医学院 730030
- From:
Chinese Journal of Neurology
2020;53(7):520-527
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor (CGRP-mAbs) on migraine.Methods:Database of PubMed, Embase, Cochrane, CNKI, Wangfang digital journals were searched for randomized controlled trials (RCTs) of CGRP-mAbs in treatment of migraine. Quality of enrolled literature was assessed by the software of Review Manager 5.3 and software of StataMP14 was employed to conduct meta analysis.Results:A total of 13 RCTs were included, including 6 218 adult migraine patients (experimental group: 2 679 patients, placebo group: 3 539 patients). Meta analysis suggested that CGRP-mAbs for preventive treatment of migraine significantly reduced the monthly migraine days from baseline (standardized mean difference (SMD)=-0.35, 95% CI-0.4--0.3) and monthly acute migraine-specific medication consumption from baseline (SMD=-0.38, 95% CI-0.43--0.32), as compared with placebo group. CGRP-mAbs for preventive treatment of migraine significantly increased the ≥50% reduction from baseline in migraine days per month ( RR=1.65, 95% CI 1.54-1.76). The adverse events were similar between the CGRP-mAbs group and placebo group ( RR=1.06, 95% CI 1.01-1.10). Conclusion:CGRP-mAbs are effective and safe for preventive treatment of migraine.
